Sanne Høxbroe Michaelsen

Sanne Høxbroe Michaelsen

Auto-generated profile, based on publicly available information

Sanne Høxbroe Michaelsen

Research Unit for ORL – Head & Neck Surgery and Audiology, Odense University Hospital, Odense, Denmark

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2017 in European Journal of Cancer
Verified
Journal Article
Closed access
SMSanne Høxbroe Michaelsen
Sanne Høxbroe Michaelsen
CGChristian Gronhoj
Christian Gronhoj
JMJacob Høxbroe Michaelsen
Jacob Høxbroe Michaelsen
JFJeppe Friborg
Jeppe Friborg
Christian von BuchwaldChristian von Buchwald
Christian von Buchwald


18 August 2025 in Surgery
Verified
Journal Article
Open access
SMSanne H. Michaelsen
Sanne H. Michaelsen
HDHelle Døssing
Helle Døssing
Oke GerkeOke Gerke
Oke Gerke
KBKristine Bjørndal
Kristine Bjørndal
AMAnders R. Madsen
Anders R. Madsen
VNViveque E. Nielsen
Viveque E. Nielsen
This was a single-institution controlled trial examining whether the intraoperative combination of near-infrared-induced autofluorescence of the parathyroid glands and preresection indocyanine green near-infrared angiograms of the parathyroid feeding vessels can reduce the incidence of postoperative hypoparathyroidism 1 year after surgery in patients undergoing total or completion thyroidectomy. Included patients underwent total or completion thyroidectomy. The intervention group was prospective and underwent surgery with bimodal near-infrared-induced autofluorescence of the parathyroid glands and preresection indocyanine green near-infrared angiograms. The control group was retrospective and underwent standard surgery. Patients were matched with a 1:3 ratio for intervention/control. Minimal matching criteria were procedure (completion/total thyroidectomy), surgical indication (compressive symptoms/hyperthyroidism/suspicion or diagnosis of cancer), substernal goiter, and lymph node resection/neck dissection. The primary outcome was hypoparathyroidism 1 year after surgery, defined as treatment with an active vitamin D analogue. A total of 154 intervention patients were included and matched with 462 control patients. The incidence of hypoparathyroidism 1 year after surgery was 6.5% in the intervention group and 12.3% in the control group. The risk of hypoparathyroidism 1 year after surgery was significantly lower in the intervention group compared with control patients (odds ratio, 0.50; 95% confidence interval, 0.248-0.996). The difference was even more pronounced after adjustment for potential confounders (sex, age, body mass index, perioperative blood loss, weight of both thyroid lobes, former central neck surgery, operating surgeon) (odds ratio, 0.16; 95% confidence interval, 00.048-0.560). The bimodal application of near-infrared-induced autofluorescence of the parathyroid glands and pre-resection indocyanine green near-infrared angiograms during total and completion thyroidectomy significantly reduces the risk of hypoparathyroidism 1 year after surgery.

1 June 2023 in JAMA Otolaryngology–Head & Neck Surgery
Verified
Journal Article
Open access
PDF file
SMSanne Høxbroe Michaelsen
Sanne Høxbroe Michaelsen
MBMette Bay
Mette Bay
Oke GerkeOke Gerke
Oke Gerke
SVSys Vestergaard
Sys Vestergaard
OGOle Graumann
Ole Graumann
CGChristian Godballe
Christian Godballe
Importance: Scintigraphy and ultrasonography are common imaging modalities for the preoperative localization of enlarged parathyroid glands in primary hyperparathyroidism. When comparing the 2 modalities, the benefits of ultrasonography in terms of convenience, patient comfort, duration, cost, and lack of radiation should be taken into account.Objective: To investigate whether surgeon-performed ultrasonography, with or without contrast-enhanced ultrasonography (CEUS), is noninferior to scintigraphy for localizing pathological parathyroid glands in patients with primary hyperparathyroidism.Design, Setting, and Participants: Prospective, paired, noninferiority cohort study performed at a high-volume tertiary referral center for parathyroidectomy with blinded examiners and a 6-month follow-up. Participants were adults (age ≥18 years) referred for parathyroidectomy due to primary hyperparathyroidism. Of 207 eligible patients, 35 were excluded, leaving 172 enrolled in the study. Inclusion lasted from September 2019 until February 2021. Follow-up ended in December 2021.Exposures: 99mTechnetium-pertechnetate/99mtechnetium-sestamibi subtraction scintigraphy with 99mtechnetium-sestamibi single-photon emission computed tomography/computed tomography, followed by surgeon-performed ultrasonography and CEUS.Main Outcomes and Measures: The sensitivity of each imaging modality in localizing pathological parathyroid glands, calculated on a per-quadrant and a per-patient basis, respectively. The a priori noninferiority margin was a lower 95% confidence limit for the difference in sensitivity not falling below −10%.Results: Out of 172 participants, 139 (80.8%) were women, the median (range) age was 65 (24-87) years, and the median (IQR) follow-up was 200.5 (181-280.25) days. Quadrant sensitivity (95% CI) was 70.9% (63.2%-78.5%) for ultrasonography, 68.4% (60.4%-76.5%) for ultrasonography plus CEUS, and 67.0% (60.0%-74.0%) for scintigraphy. The sensitivity difference (95% CI) compared with scintigraphy was 3.9% (−4.1% to 11.8%) for ultrasonography and 1.5% (−6.4% to 9.3%) for ultrasonography plus CEUS, establishing noninferiority for both modalities. Per-patient sensitivity was 81.4% (74.8%-86.9%) for ultrasonography and 79.1% (72.2%-84.9%) for both scintigraphy and ultrasonography plus CEUS. The sensitivity difference compared with scintigraphy was 2.3% (−6.8% to 11.4%) for ultrasonography and 0.0% (−9.1% to 9.1%) for ultrasonography plus CEUS, establishing noninferiority for both modalities.Conclusions and Relevance: In this cohort study, conventional ultrasonography by an experienced parathyroid surgeon-sonographer was noninferior to scintigraphy and may constitute a valid first-line imaging modality in patients with primary hyperparathyroidism, even without the addition of CEUS. Further imaging should be reserved for cases that are equivocal or nonlocalizing on ultrasonography.

15 January 2019 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
SMSanne Høxbroe Michaelsen
Sanne Høxbroe Michaelsen
MOMarie Juul Ornstrup
Marie Juul Ornstrup
MPMorten Møller Poulsen
Morten Møller Poulsen
FBFinn Noe Bennedbæk
Finn Noe Bennedbæk
MGMette Gaustadnes
Mette Gaustadnes
JMJes Sloth Mathisen
Jes Sloth Mathisen

30 June 2025 in Endocrine
Verified
Journal Article
Open access
PDF file
SMSanne Høxbroe Michaelsen
Sanne Høxbroe Michaelsen
Oke GerkeOke Gerke
Oke Gerke
CGChristian Godballe
Christian Godballe
SBSteen Joop Bonnema
Steen Joop Bonnema
VNViveque Egsgaard Nielsen
Viveque Egsgaard Nielsen
Purpose: This single-center retrospective study investigates the incidence of hypoparathyroidism after bilateral thyroidectomy at a tertiary referral center over one decade, including risk factors, time to recovery, and reasons for belated treatment initiation in seemingly “late onset” hypoparathyroidism. Methods: Patients who underwent total/completion thyroidectomy from January 2011 to December 2020 were included. Potential risk factors for hypoparathyroidism were retrieved from the medical records. Hypoparathyroidism was defined as treatment with an activated vitamin D analogue (AVDA). The incidence was registered 0, 6, 12, and >12 months postoperatively. Hospital records were cross-linked with the national prescription database to ensure complete follow-up. Results: The incidence of hypoparathyroidism increased from 10.1% upon hospital discharge to 11.4% after 6 months, 12.2% after 12 months, and 12.6% >12 months (median follow-up 7.7 years). The cumulative recovery rate was 19.9% by 6 months, 23.6% by 12 months, and 29.8% >12 months. As many as 23.3% of patients with persistent hypoparathyroidism did not start AVDA treatment within 6 months of surgery, and 12.0% started treatment beyond one year after surgery. In contrast, 9.3% of patients receiving AVDA by 12 months went into remission later on. Two variables emerged as independent risk factors for persistent hypoparathyroidism: re-operation for bleeding (OR 4.21; 95%CI 1.31–13.38) and surgery due to a diagnosis/suspicion of thyroid cancer (OR 2.09; 95%CI 1.04–4.19). Conclusion: The incidence of postoperative hypoparathyroidism is high and calls for action. Importantly, reassessment of post-surgical parathyroid function should be done regularly in order to neither overlook “late onset” hypoparathyroidism, nor late remission.